Intelligence Feed event · Equity · 2026-09-18

    Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary

    Question

    Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary

    Direct answer

    Eli Lilly disclosed $27.7 billion in first-half 2026 revenue generated by its GLP-1 portfolio, led by Mounjaro and Zepbound. The scale reinforces dominant market share in metabolic treatments. Oral obesity candidate Foundayo obtained broad formulary coverage across primary PBM networks. In addition, newer therapies outside the primary metabolic portfolio grew 121% in Q2.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-18
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary”, revision 1, evidence through 2026-09-18. https://marketontology.com/market-events/2026-09-18/eli-lilly-generates-27-7b-in-1h-glp-1-sales-as-foundayo-gains-pbm-formulary-bb9fe4

    EQUITY
    Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
    Eli Lilly disclosed $27.7 billion in first-half 2026 revenue generated by its GLP-1 portfolio, led by Mounjaro and Zepbound. The scale reinforces dominant market share in metabolic treatments. Oral obesity candidate Foundayo obtained broad formulary coverage across primary PBM networks. In addition, newer therapies outside the primary metabolic portfolio grew 121% in Q2.
    LLYNVO
    Impact
    65
    SEP 18
    SIG
    85%
    LLYNVO
    Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
    Eli Lilly disclosed $27.7 billion in first-half 2026 revenue generated by its GLP-1 portfolio, led by Mounjaro and Zepbound. The scale reinforces dominant market share in metabolic treatments. Oral obesity candidate Foundayo obtained broad formulary coverage across primary PBM networks. In addition, newer therapies outside the primary metabolic portfolio grew 121% in Q2.
    → Broad PBM formulary coverage for oral obesity drug Foundayo expands addressable patient volume and supports long-term revenue diversification for LLY.
    Impact
    Eli Lilly disclosed $27.7 billion in first-half 2026 revenue generated by its GLP-1 portfolio, led by Mounjaro and Zepbound. The scale reinforces dominant market share in metabolic treatments. Oral obesity candidate Foundayo obtained broad formulary coverage across primary PBM networks. In addition, newer therapies outside the primary metabolic portfolio grew 121% in Q2.
    Affected
    LLYNVO
    Transmission
    Broad PBM formulary coverage for oral obesity drug Foundayo expands addressable patient volume and supports long-term revenue diversification for LLY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYoral metabolic drug commercial access and volume expansionUp1-3mRecorded $27.7B in 1H GLP-1 sales and secured major PBM coverage for Foundayo.
    NVOobesity drug pricing competition and market share divisionWatch1-3mPrimary peer in GLP-1 metabolic franchise.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    NVOWatch43.24 2026-09-18-7.96%-10.27%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month